The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Open accessAbstract
Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a complex consisting of YAP, TAZ, TEADs, and AP-1 (dimer of cFos and transcription factor Jun [JUN] families) was found to synergistically regulate the transcription of target genes (35–37).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have demonstrated that activated Yap, through genetic amplification of YAP- or WNT5a-mediated dysregulation of the Hippo pathway, enables bypass of Kras suppression in Kras-driven murine pancreatic cancer and lung cancer models (37–39).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“YAP, a pivotal EMT regulator gene, can restore oncogenicity in murine tumors that have lost KRAS [54,131].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior studies using inducible suppression of KRAS via RNA interference or genetically engineered inducible KrasG12D alleles (i.e., “iKras” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRASG12D suppression (35–38).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using a genetically engineered mouse (GEM) model of PDAC driven by inducible KRASG12D, we recently demonstrated that activation of the YAP1 oncogene drives resistance to genetic inactivation of KRAS∗, a finding further confirmed in KRAS∗-driven colorectal cancer (CRC).”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The YAP1 oncogene has been well established as one of the major drivers of bypassing oncogene addiction and promoting acquired resistance to targeted therapies in several cancer types, including pancreatic cancer, lung cancer, colorectal cancer, melanoma, and glioblastoma.9,10,38,39,40”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“In the context of pancreatic cancer, KRAS dependency can be by-passed by the elevated expression of the transcription factor YAP1, which promotes EMT and confers cell-intrinsic resistance to KRAS loss (84, 85).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [84]
In the citing paper
“On the one hand, it is known that YAP activity is positively correlated with the resistance to therapies targeting KRAS signaling components including RAF and MEK,[ 28, 46 ] and YAP is required for KRAS‐dependent cell transformation: extracellular supplementation of YAP activators can rescue cancer cell killing after KRAS knockdown.[ 47 ]”
From Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Self-citationTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,423
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citation
Flagged first, then by citations
1 of the 69 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 753
Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer
Zhang, S., Wei, Q., Yang, Y. P., Qin, H., Li, X., Cai, S., & Ma, Y. (2019) · Journal of Cancer · doi:10.7150/jca.28333 · Cited by 14
Han, X., Sun, T., Hong, J., Wei, R., Dong, Y., Huang, D., Chen, J., Ren, X., Zhou, H., Tian, W., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29038 · Cited by 14
Yuan, Y., Wang, J., Xu, M., Zhang, Y., Wang, Z., Liang, L., & Sun, P. (2020) · Bioscience Reports · doi:10.1042/bsr20191507 · Cited by 14
Hsu, P., Li, J., & Yang, C. (2022) · Biomedicines · doi:10.3390/biomedicines10071704 · Cited by 14
YAP/TAZ enhances P-body formation to promote tumorigenesis
Shen, X., Peng, X., Guo, Y., Dai, Z., Cui, L., Yu, W., Liu, Y., & Liu, C. (2023) · eLife · doi:10.7554/elife.88573 · Cited by 21
Hao, B., Chen, X., & Cao, Y. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6322 · Cited by 13
Follistatin Like 5 (FSTL5) inhibits epithelial to mesenchymal transition in hepatocellular carcinoma
Zhang, D., Lei, J., Sun, W., Wang, D., & Lü, Z. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000847 · Cited by 13
Zhou, J., Zhang, S., Li, Z., Chen, Z., Xu, Y., Ye, W., & He, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108754 · Cited by 13
RetractedKhan, T., Scott, K. F., Becker, T. M., Lock, J. G., Nimir, M., Ma, Y., & SOUZA, P. D. (2020) · Prostate Cancer · doi:10.1155/2020/7938280 · Cited by 13
Xu, T., Wei, D., Yang, Z., Xie, S., Yan, Z., Chen, C., Hu, W., Shi, Z., Zhao, Y., Cui, M., et al. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109642 · Cited by 13
Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers
Biersack, B., Tahtamouni, L. H., & Höpfner, M. (2024) · Receptors · doi:10.3390/receptors3010005 · Cited by 16
PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
Wang, P., Wei, D., Zhang, H., Chen, J., Zhang, D., Ganapathy, S., Isakson, P., Chen, C., & Zhu, T. (2018) · Oncotarget · doi:10.18632/oncotarget.25127 · Cited by 12
Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai, H., Matsuoka, R., Ito, T., & Matsubara, D. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2703108 · Cited by 12
Kim, H. Y., Moon, J. Y., & Cho, S. K. (2023) · Journal of Medicinal Food · doi:10.1089/jmf.2022.k.0061 · Cited by 12
Seton-Rogers, S. E. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3791 · Cited by 12
Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
Oh, H., Hwang, I., Jang, J.-Y., Wu, L., Cao, D., Yao, J., Ying, H., Li, J. Y., Yao, Y., Hu, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1810 · Cited by 11
KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., et al. (2024) · Cancers · doi:10.3390/cancers16203455 · Cited by 11
A Novel PHD2/VHL-mediated Regulation of YAP1 Contributes to VEGF Expression and Angiogenesis
Bora-Singhal, N., Saha, B., Mohankumar, D., Padmanabhan, J., Coppola, D., & Chellappan, S. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0084 · Cited by 11
Systematic loss-of-function screens identify pathway-specific functional circular RNAs
Liu, L., Neve, M., Perlaza-Jiménez, L., Xi, X., Purcell, J., Hawdon, A., Conn, S. J., Zenker, J., Tamayo, P., Goodall, G. J., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01467-y · Cited by 10
Self-citationThe Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer
Zhong, B., Du, J., Liu, F., & Sun, S. (2025) · MedComm · doi:10.1002/mco2.70128 · Cited by 10
Yorkie-Cactus (IκBα)-JNK axis promotes tumor growth and progression in Drosophila
Snigdha, K., Singh, A., & Kango-Singh, M. (2021) · Oncogene · doi:10.1038/s41388-021-01831-4 · Cited by 11
MicroRNA–Gene Interactions Impacted by Toxic Metal(oid)s during EMT and Carcinogenesis
Tran, F., Lee, E., Cuddapah, S., Choi, B. H., & Dai, W. (2022) · Cancers · doi:10.3390/cancers14235818 · Cited by 11
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality
Donahue, T. R., & Dawson, D. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.009 · Cited by 11
Livin promotes tumor progression through YAP activation in ovarian cancer.
Gao, J., Han, W., He, Y., Zhou, J., Miao, J., & Zhang, G. (2020) · PubMed Central · Cited by 11
Li, C., Peng, Z., Wang, Y., Lam, G., Nissen, N. N., Tang, J., Yuan, X., Lewis, M. S., Greene, M. I., Pandol, S. J., et al. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00185.2020 · Cited by 11
Potential mechanism of circRNA_000585 in cholangiocarcinoma
Yi, F., Xin, L., & Feng, L. (2021) · Journal of International Medical Research · doi:10.1177/03000605211024501 · Cited by 11
RAS and PP2A activities converge on epigenetic gene regulation
Aakula, A., Sharma, M., Tabaro, F., Nätkin, R., Kamila, J., Honkanen, H., Schapira, M., Arrowsmith, C. H., Nykter, M., & Westermarck, J. K. (2023) · Life Science Alliance · doi:10.26508/lsa.202301928 · Cited by 12
Nader, N. A., Ménard, A., Levasseur, A., St‐Jean, G., Boerboom, D., Zamberlam, G., & Boyer, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113585 · Cited by 10
Xu, T., Liu, K., Zhang, Y., Chen, Y., & Yin, D. (2024) · Environmental Science and Pollution Research · doi:10.1007/s11356-024-33872-z · Cited by 10
A non-canonical repressor function of JUN restrains YAP activity and liver cancer growth
Kurlishchuk, Y. V., Vranesic, A. C., Jessen, M., Kipping, A., Ritter, C., Kim, K., Cramer, P., & von Eyß, B. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00188-0 · Cited by 10
YAP promotes global mRNA translation to fuel oncogenic growth despite starvation
Hwang, D., Baek, S., Chang, J., Seol, T., Ku, B., Ha, H., Lee, H., Cho, S., Roh, T., Kim, Y. K., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01316-w · Cited by 12
Kale, R. R., Samant, C., Nandakumar, K., Pai, K. S. R., & Bhonde, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151688 · Cited by 11
He, X., Ballestas, E. R., Zeng, L., Zhang, T., McEvoy, C. M., Misra, P. S., Ki, V., Apostol, A. J., Wong, J., Meliambro, K. A., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq3852 · Cited by 10
Cunningham, R., Jia, S., Purohit, K. P., Nosková, M., Maniak, M. K., Lin, Y., Hui, N. S., Graham, R. E., Rossi, A. G., Cholewa-Waclaw, J., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202503241 · Cited by 12
MUC13 drives cancer aggressiveness and metastasis through the YAP1-dependent pathway
Doxtater, K. D., Tripathi, M. K., Sekhri, R., Hafeez, B. B., Khan, S., Zafar, N., Behrman, S. W., Yallapu, M. M., Jaggi, M., & Chauhan, S. C. (2023) · Life Science Alliance · doi:10.26508/lsa.202301975 · Cited by 10
Mohamed, A. D., Shah, N., Hettmer, S., Vargesson, N., & Wackerhage, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-33852-7 · Cited by 10
Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer
Haley, J. D., Ruiz, C. F., Montal, E. D., Wang, D., Haley, J. D., & Girnun, G. D. (2019) · Cancers · doi:10.3390/cancers11101488 · Cited by 10
An updated patent review of TEAD modulators (2022–present)
Xu, D., Zhong, J., Zeng, Y., Zhang, X., Wang, C., Luo, C., & Xiong, H. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2522747 · Cited by 9
Hao, F. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02826-7 · Cited by 10
KAT7 promoted gastric cancer progression through promoting YAP1 activation
Guo, X., Li, Y., Wan, B., Lv, Y., Wang, X., Liu, G., & Wang, P. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154020 · Cited by 9
Self-citationMurakami, S., White, S. M., McIntosh, A. T., Nguyen, C. D. K., & Yi, C. (2023) · Nature Communications · doi:10.1038/s41467-023-37147-y · Cited by 9
Wang, Y., Jin, S.-S., Li, D., Jiang, X., Afrasiyab, A., Khalid, A., Liu, X., Wang, H., Wang, H.-Y., Wang, Z.-G., et al. (2023) · PubMed Central · doi:10.62347/vdjo7647 · Cited by 9
CFC1 is a cancer stemness-regulating factor in neuroblastoma
Chikaraishi, K., Takenobu, H., Sugino, R. P., Mukae, K., Akter, J., Haruta, M., Kurosumi, M., Endo, T. A., Koseki, H., Shimojo, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18464 · Cited by 9
Lili, L. N., Huang, A. D., Zhang, M., Wang, L., McDonald, L. D., Matyunina, L. V., Satpathy, M., & McDonald, J. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.001 · Cited by 9
Groth, C., Vaid, P. M., Khatpe, A. S., Prashali, N., Ahiya, A., Andrējeva, D., Chakladar, M., Nagarkar, S., Paul, R., Kelkar, D. A., et al. (2020) · G3 Genes Genomes Genetics · doi:10.1534/g3.120.401545 · Cited by 8
Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer
Wu, Y., Huang, H., Fervers, B., & Lu, L. (2020) · Pancreas · doi:10.1097/mpa.0000000000001654 · Cited by 9
MicroRNA‑199a‑3p inhibits ovarian cancer cell viability by targeting the oncogene YAP1
He, Y., Yu, X., Tang, Y., Guo, Y., Yuan, J., Bai, J., Yao, T., & Wu, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11876 · Cited by 9
RetractedYun, S. J., Jun, K.-J., Komori, K., Lee, M. J., Kwon, M., Chwae, Y., Kim, K. H., Shin, H., & Park, S. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.05.014 · Cited by 9
Ras Post-transcriptionally Enhances a Pre-malignantly Primed EMT to Promote Invasion
Bisogno, L. S., Friedersdorf, M. B., & Keene, J. D. (2018) · iScience · doi:10.1016/j.isci.2018.05.011 · Cited by 9
Loss of Wasl improves pancreatic cancer outcome
Hidalgo‐Sastre, A., Desztics, J., Dantes, Z., Schulte, K., Kabadayı, H., Bassey-Archibong, B. I., Öllinger, R., Engleiter, T., Rayner, L. G. A., Einwächter, H., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.127275 · Cited by 9
PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
Killarney, S. T., Mesa, G., Washart, R., Mayro, B., Dillon, K. A., Wardell, S. E., Newlin, M., Lu, M., Rmaileh, A. A., Liu, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0928 · Cited by 9
Wang, S., Diao, S., Kim, H., Zou, J. Y., Li, K., & Koromilas, A. E. (2025) · Communications Biology · doi:10.1038/s42003-025-08740-2 · Cited by 8
Pan, C., Du, Z., Cai, Z., Liu, Y., Sun, Y., Chen, J., Tong, T., Chen, Q., Zhou, L., Bing, D., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7187 · Cited by 8
Lu, Y., Mu, Y., Chen, J., Guan, X., Guo, L., & Wu, C. (2022) · Theranostics · doi:10.7150/thno.72365 · Cited by 8
New Horizons in Cancer Progression and Metastasis: Hippo Signaling Pathway
Kuracha, M. R., Radhakrishna, U., Kuracha, S. V., Vegi, N., Gurung, J. L., & McVicker, B. L. (2024) · Biomedicines · doi:10.3390/biomedicines12112552 · Cited by 8
Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions
Reis, H., Bertram, S., Pott, L. L., Canbay, A. E., Gallinat, A., & Baba, H. A. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0079-0 · Cited by 8
Giannopoulou, A. F., Velentzas, A. D., Anagnostopoulos, A. K., Agalou, A., Papandreou, N. C., Katarachia, S. A., Koumoundourou, D. G., Konstantakou, E. G., Pantazopoulou, V. I., Delis, A. D., et al. (2021) · Cancers · doi:10.3390/cancers13092024 · Cited by 8
Recent insight into the role and therapeutic potential of YAP/TAZ in gastrointestinal cancers
Wang, Y., Chen, H., Yu, J. Q., Kang, W., & To, K. F. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188787 · Cited by 8
Expression of EMT-related genes in lymph node metastasis in endometrial cancer: a TCGA-based study
Li, H., Junzhu, W., Liwei, L., Zhao, L., & Wang, Z. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-02893-2 · Cited by 8
Chen, X.-X., Li, S., Yu, Z., & Tan, W. (2019) · Europe PMC (PubMed Central) · Cited by 8
Zhao, Z., Liu, W., & Luo, B. (2025) · Gene · doi:10.1016/j.gene.2025.149312 · Cited by 7
Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway
Xie, Y., Qin, C. Y., Zhang, X., Li, Z., Zhao, B., Li, T., Zhao, Y., Yan, Y., Shi, H., Huang, L., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217864 · Cited by 7
Holubeková, V., Loderer, D., Grendár, M., Mikolajčík, P., Kolková, Z., Turyova, E., Kúdelová, E., Kalman, M., Marcinek, J., Miklušica, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1206482 · Cited by 7
Interaction of noncoding RNAs with hippo signaling pathway in cancer cells and cancer stem cells
Abedimanesh, S., Safaralizadeh, R., Jahanafrooz, Z., Najafi, S., Amini, M. A., Nazarloo, S. S., Mahdavi, S. Z. B., Baradaran, B., Jebelli, A., & Mokhtarzadeh, A. A. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.06.006 · Cited by 7
RASpecting the oncogene: New pathways to therapeutic advances
Stout, M. C., & Campbell, P. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.022 · Cited by 7
Breast Tissue Biology Expands the Possibilities for Prevention of Age-Related Breast Cancers
Fresques, T., Zirbes, A., Shalabi, S., Samson, S., Preto, S., Stampfer, M. R., & LaBarge, M. A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00174 · Cited by 7
Mikula, M. W., Najjar, S. N., Jabbour, T. E., Dalvi, S., Umrau, K., Li, H., Koo, B. H., & Lee, H. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000888 · Cited by 7
Hippo‐YAP signaling activation and cross‐talk with PI3K in oral cancer: A retrospective cohort study
Rodrigo, J. P., Rodríguez‐Santamarta, T., Corte-Torres, M. D., García-de-la-Fuente, V., Rodríguez‐Torres, N., Lequerica–Fernández, P., Lorz, C., Garcia-Pedrero, J. M., & de Vicente, J. C. (2022) · Oral Diseases · doi:10.1111/odi.14350 · Cited by 8
Ferguson, R., Aughton, K., Evans, A., Shaw, V. E., Armstrong, J. A., Ware, A., Bennett, L. G., Costello, E., & Greenhalf, W. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030164 · Cited by 7
Slaninová, V., Héron‐Milhavet, L., Robin, M., Jeanson, L., Aissanou, A., Kantar, D., Tosi, D., Bréhélin, L., Gongora, C., & Djiane, A. (2024) · BMC Cancer · doi:10.1186/s12885-024-12316-4 · Cited by 8
Sawabata, N. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.63 · Cited by 7
Arias-García, M., Yin, Z., Roumeliotis, T. I., Butera, F., Wang, L., Rickman, R. H., Choudhary, J. S., Wong, S. T. C., Yuan, Y., & Bakal, C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/689737 · Cited by 7
Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6
Self-citationHu, P., Dou, R., Qi, Z., Liu, G., & Su, Y. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.70006 · Cited by 6
Hippo signaling in mechanobiology: Mechanical control of YAP/TAZ and their roles in disease
Kim, Y., Lee, H., Lee, J.-H., Kim, W., & Cha, B. (2026) · Mechanobiology · doi:10.1177/29780241261430920 · Cited by 7
Ouyang, H., Wu, S., Li, W., Grey, M. J., Wu, W., & Hansen, S. H. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113486 · Cited by 6
YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes
Chen, H., Shang, Y., Li, X., & Wang, R. (2024) · Cell Cycle · doi:10.1080/15384101.2024.2309017 · Cited by 6
Clarke, L. E., Cook, A., Mathavarajah, S., Bera, A., Salsman, J., Habib, E. B., Iderstine, C. V., Bydoun, M., Lewis, S. M., & Dellaire, G. (2021) · The FASEB Journal · doi:10.1096/fj.202001063r · Cited by 6
Sun, X., Zhang, J., Dong, J., Liu, L., Li, X., Xing, P., Ying, J., Che, Y., Li, J., & Yang, L. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101538 · Cited by 6
Shen, M., Su, Y., Song, S., Liu, D., Liu, Z., Chen, D., Pan, Y., Zhang, L., & Xu, X. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.3.8 · Cited by 6
Cao, F., Jiang, Y., Chang, L., Du, H., Chang, D., Pan, C., Huang, X., Yu, D., Zhang, M., Fan, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05951-5 · Cited by 6
Wang, M., Xu, H., Han, Q., & Wang, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2237040 · Cited by 6
Han, T., Cheng, Z., Xu, M., Wang, X., Wu, J., & Fang, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266449 · Cited by 6
Self-citationCheng, Y., Huang, H., Han, Y., & Zhu, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-3155 · Cited by 6
Ott, C. A., Purwin, T. J., Chen, P., Chowdhury, S., Mellor, G. L., Luo, K., Mersky, G. L., Tiago, M., Madden, W. D. B., Varney, S. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64682-7 · Cited by 6
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 6
Chen, H., Li, Y., Wu, G., Zeng, Q.-M., Huang, H., & Zhang, G. (2024) · European journal of medical research · doi:10.1186/s40001-024-01645-6 · Cited by 5
Ester, L., Wiesner, E., Chen, H., Ventzke, M. T., Diefenhardt, P., Mandel, A. M., Fabretti, F., Brinkkoetter, P. T., Benzing, T. R., Habbig, S., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000689 · Cited by 5
Synthetic lethality through Gsk3β inhibition in glioma stem cells via the WNT-WWC1-YAP axis
Ren, F., Yi, Y., Lu, T., Liu, X., Cui, G., Huang, S. M., Parada, L. F., & Chen, J. (2025) · Oncogene · doi:10.1038/s41388-025-03418-9 · Cited by 7
Hippo Pathway Key to Ploidy Checkpoint
Zhao, B., & Guan, K. (2014) · Cell · doi:10.1016/j.cell.2014.07.041 · Cited by 6
Lee, Y., Lee, J.-Y., Song, S.-H., Kim, D.-M., Lee, J.-W., Chi, X., Ito, Y., & Bae, S. (2020) · PubMed Central · doi:10.14348/molcells.2020.0182 · Cited by 5
Role of Yes-associated Protein-1 in Gastrointestinal Cancers and Hepatocellular Carcinoma
Qian, X., Zhang, W., Yang, H., Zhang, L., Kang, N., & Lai, J. (2021) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00017 · Cited by 5
Koromilas, A. E. (2022) · BioEssays · doi:10.1002/bies.202200026 · Cited by 5
El-Deek, H. E. M., Elnaggar, M., Morsy, A., Sedik, M. F., Osman, H. A., & Ahmed, A. M. (2024) · Medical Molecular Morphology · doi:10.1007/s00795-024-00385-0 · Cited by 5
Huo, C., Kuo, Y., Lin, C., Shiah, S., Li, C., Huang, S., Chen, J., Wang, W., Kung, H., & Chuu, C. (2024) · Cancer Medicine · doi:10.1002/cam4.70106 · Cited by 4
The RAS and YAP1 dance, who is leading?
Corbo, V., Ponz‐Sarvisé, M., & Tuveson, D. A. (2014) · The EMBO Journal · doi:10.15252/embj.201490014 · Cited by 5
RASSF1A methylation, YAP1 activation and metastasis: a new role for an old foe in lung cancer
Oh, M. H., & Lockwood, W. W. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.04.16 · Cited by 5
Maietta, I., Domínguez-Arístegui, P., Álvarez, I. G., Atanes, O. R., Fontán, E. M. G., Teijeira, S., González‐Fernández, Á., & Simón‐Vázquez, R. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126155 · Cited by 5
Ma, L., Xu, M. M., Xu, S., Guo, X., Zong, W., Zhao, X., Yang, Z., Liu, G., & Shen, L. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00963-z · Cited by 4
Hagenbeek, T. J., Zbieg, J. R., Smith, R., Paul, S., Gerosa, L., Torrini, C., Guarnaccia, A. D., Ong, C. C., Lacap, J. A., Ning, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74722-5 · Cited by 4
Metadata
- Authors
- Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., Zwang, Y., Roberts, T. M., Root, D. E., Jacks, T., & Hahn, W. C.
- Affiliations
- Broad Institute (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Jacks, Tyler
- Hahn, William C.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 158
- Issue
- 1
- Pages
- 171-184
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4110062
- OpenAlex
- W2064644124
- Cited by
- 744
- References
- 69
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 50 · 2023: 56 · 2022: 59 · 2021: 58 · 2020: 82 · 2019: 68 · 2018: 58 · 2017: 73 · 2016: 75 · 2015: 61 · 2014: 22
- FWCI
- 38.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (P30-CA14051, W81XWH)
- Howard Hughes Medical Institute
- American Association for Cancer Research
- Hope Funds for Cancer Research (HFCR-11-03-03)
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051)
- National Institutes of Health (W81XWH)
- National Cancer Institute (P50CA127003, K99CA169512, R01CA140545, CA14051, R00CA169512, P01CA050661, U01CA176058, P01CA154303, P30CA014051, P30-CA-14051)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- KRAS, YAP, oncogenic Ras, epithelial-mesenchymal transition, tumor cell survival, FOS, transcriptional coactivator, acquired drug resistance, colon cancer, lung cancer, cell transformation, transcriptional regulation
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Survival, Colonic Neoplasms, Humans, Lung Neoplasms, Phosphoproteins, Proto-Oncogene Proteins, Transcription Factors, Signal Transduction, Transcriptional Activation, Proto-Oncogene Proteins p21(ras), Drug Delivery Systems, ras Proteins, Cell Cycle Proteins, Drug Resistance, Neoplasm, HCT116 Cells, Adaptor Proteins, Signal Transducing, Mice, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
